Winston Pharmaceuticals, Inc. (WPHM) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerWinston Pharmaceuticals, Inc. (WPHM) trades at $0.0001. Winston Pharmaceuticals, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing therapeutics for various pain management indications. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for WPHM: WPHM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Winston Pharmaceuticals, Inc. (WPHM) Healthcare & Pipeline Overview
Winston Pharmaceuticals, Inc. is a U.S.-based pharmaceutical entity specializing in the discovery, development, and commercialization of therapeutics for diverse pain management indications. The company focuses on addressing unmet needs across episodic cluster headache, chronic migraine, neuropathic pain, and inflammatory pain conditions, positioning itself within the specialized healthcare sector.
What Is the Investment Thesis for WPHM?
Winston Pharmaceuticals, Inc. operates within the high-potential, yet high-risk, pharmaceutical sector, specifically targeting diverse pain management indications. The company's focus on areas like episodic cluster headache, chronic migraine, neuropathic pain, and inflammatory pain in conditions such as arthritis and IBD represents a strategic pursuit of markets with significant unmet medical needs. While the gross margin of 99.4% suggests a business model with minimal cost of goods sold, potentially indicating a pre-commercialization stage or a focus on intellectual property, the reported profit margin of -190.4% and negative free cash flow of $-0.00B highlight the substantial R&D investments and operational costs typical of drug development, without significant revenue generation to offset them. The company's market capitalization of $0.00B further indicates a very early-stage, thinly traded, or illiquid entity. Future value drivers are intrinsically linked to successful clinical trial outcomes, regulatory approvals, and eventual commercialization of its therapeutic candidates. However, the inherent uncertainties of drug development, coupled with the company's small scale and current financial performance, present considerable risks for investors.
Based on FMP financials and quantitative analysis
WPHM Key Highlights
Gross Margin of 99.4% indicates minimal cost of goods sold, potentially reflecting a pre-revenue or research-focused operational phase.
- Profit Margin of -190.4% underscores significant operating expenses and R&D investments relative to revenue, typical for a development-stage pharmaceutical company.
- Free Cash Flow (FCF) of $-0.00B confirms substantial cash outflows, consistent with a company in the drug discovery and development phase.
- Market Capitalization of $0.00B suggests a very small market valuation, potentially indicating low liquidity or an early-stage private company status despite being publicly listed.
- A workforce of 9 employees highlights a highly specialized and lean operational structure, focusing resources on core development activities.
Who Are WPHM's Competitors?
WPHM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WPHM's Key Strengths?
Specialized focus on high-need pain management indications, addressing significant unmet medical needs.
- High gross margin (99.4%) suggests a strong potential for profitability if products reach commercialization.
- Established since 1998, indicating long-term commitment to the pharmaceutical sector.
- Lean operational structure with 9 employees, potentially allowing for agile R&D.
What Are WPHM's Weaknesses?
Negative profit margin (-190.4%) and negative free cash flow ($-0.00B) indicate substantial ongoing losses.
- Market capitalization of $0.00B suggests a very small or illiquid market presence, potentially limiting access to capital.
- Small employee base (9 employees) may limit the scope and speed of multiple drug development programs.
- High beta (-982.38) is an extreme outlier, suggesting very low trading volume or data anomaly, indicative of high volatility or illiquidity.
What Are the Key Risks for WPHM?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- High attrition rate in pharmaceutical R&D, where many drug candidates fail in clinical trials or face regulatory rejection.
- Significant capital requirements for drug development, which may lead to further dilution for existing shareholders given the current financial state.
- Intense competition from established pharmaceutical companies with greater resources and multiple pain management products.
- Regulatory hurdles and lengthy approval processes that can delay or prevent the commercialization of any developed therapeutics.
- Limited liquidity and investor awareness due to trading on the OTC Other tier with unknown disclosure status, impacting valuation and capital access.
What Threats Does WPHM Face?
- High risk of clinical trial failures, which is common in pharmaceutical development.
- Intense competition from larger pharmaceutical companies with greater resources and established pipelines.
- Stringent and lengthy regulatory approval processes, which can delay or prevent market entry.
- Dependence on a limited number of drug candidates, making the company highly vulnerable to setbacks in any single program.
- Challenges associated with OTC market trading, including limited liquidity and investor awareness.
What Are WPHM's Competitive Advantages?
- Potential for proprietary drug formulations and intellectual property protection through patents.
- Specialized focus on specific, often underserved, pain indications which may lead to deep expertise.
- Regulatory approvals for novel therapeutics, creating barriers to entry for competitors.
- Clinical data demonstrating superior efficacy or safety profiles for its drug candidates.
What Does WPHM Do?
Winston Pharmaceuticals, Inc., headquartered in Vernon Hills, Illinois, is a pharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics specifically designed for pain management. Incorporated in 1998, the company initially operated as Winston Laboratories, Inc. before undergoing a name change to Winston Pharmaceuticals, Inc. in November 2008, reflecting its evolving focus within the pharmaceutical landscape. The company's strategic emphasis is on a range of significant pain indications, addressing both chronic and acute conditions that present substantial challenges for patients and healthcare providers. These targeted areas include episodic cluster headache, a severe and debilitating neurological condition, and chronic migraine headache, a widespread and often disabling form of headache. Beyond primary headache disorders, Winston Pharmaceuticals also directs its research and development efforts towards neuropathic pain syndromes, which arise from nerve damage and are notoriously difficult to treat effectively. Furthermore, the company is engaged in developing solutions for the pain and inflammation associated with common musculoskeletal conditions such as osteo- and rheumatoid arthritis, which affect millions globally. A specialized focus also extends to pain and inflammation in inflammatory bowel disease, a complex condition requiring integrated therapeutic approaches. With a lean operational structure, managing 9 employees, Winston Pharmaceuticals, Inc. aims to carve out a niche in these specific therapeutic areas, seeking to bring innovative solutions to patients suffering from various forms of pain.
What Products and Services Does WPHM Offer?
- Discovers novel pharmaceutical compounds for therapeutic use.
- Develops drug candidates through preclinical and clinical trial phases.
- Aims to commercialize approved therapeutics for various pain management indications.
- Focuses on severe neurological pain conditions like episodic cluster headache and chronic migraine.
- Targets complex neuropathic pain syndromes resulting from nerve damage.
- Develops treatments for pain and inflammation associated with osteo- and rheumatoid arthritis.
- Explores solutions for pain and inflammation specifically related to inflammatory bowel disease (IBD).
- Engages in research and development for niche pain indications.
How Does WPHM Make Money?
- Involves the research and development of proprietary pharmaceutical compounds.
- Seeks to obtain regulatory approvals (e.g., FDA) for its drug candidates.
- Plans to generate revenue through the sale of commercialized pain management therapeutics.
- Relies on intellectual property, such as patents, to protect its drug formulations and mechanisms of action.
- Likely involves partnerships or licensing agreements for broader market reach or funding, though not specified in provided data.
What Industry Does WPHM Operate In?
Winston Pharmaceuticals, Inc. operates within the highly competitive and innovation-driven Medical - Pharmaceuticals industry, specifically targeting the pain management market. This segment of healthcare is characterized by a significant global burden of disease, with millions suffering from chronic and acute pain conditions, driving a continuous demand for novel and more effective therapeutics. Key market trends include a shift towards targeted therapies, a growing emphasis on non-opioid pain solutions, and advancements in understanding the biological mechanisms of pain. The competitive landscape is populated by both large multinational pharmaceutical corporations with extensive R&D pipelines and smaller, specialized biopharmaceutical firms. Winston Pharmaceuticals, with its focus on niche indications such as episodic cluster headache and specific neuropathic pain syndromes, aims to differentiate itself by addressing areas where current treatments may be inadequate or carry significant side effects. The industry is heavily regulated, with long and costly development cycles, making successful product commercialization a significant challenge for all participants.
Who Are WPHM's Key Customers?
- Patients suffering from episodic cluster headaches.
- Individuals experiencing chronic migraine headaches.
- Patients diagnosed with various neuropathic pain syndromes.
- Those with pain and inflammation due to osteo- and rheumatoid arthritis.
- Patients with inflammatory bowel disease (IBD) experiencing associated pain and inflammation.
- Healthcare providers (physicians, specialists) who prescribe pain management therapeutics.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Winston Pharmaceuticals, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Vernon Hills, US. The company is led by CEO Joel E. Bernstein. WPHM has traded publicly since 2023.
Financial Health
Winston Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
WPHM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
WPHM Latest News
No recent news available for WPHM.
WPHM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for WPHM.
Price Targets
Wall Street price target analysis for WPHM.
WPHM MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for WPHM; grades run from A+ (80-100) to F (below 30).
Leadership: Joel E. Bernstein
Unknown
Joel E. Bernstein serves as a leader at Winston Pharmaceuticals, Inc., overseeing a team of 9 employees. His leadership is central to the company's strategic direction and operational execution in its pursuit of pain management therapeutics.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Joel E. Bernstein's leadership are not detailed in the provided information. His role involves managing the company's small team and guiding its efforts in discovering, developing, and commercializing therapeutics for various pain indications.
WPHM OTC Market Information
Winston Pharmaceuticals, Inc. trades on the OTC Other tier of the OTC market. The OTC Other tier, also known as the Pink Sheets, represents companies that do not meet the minimum disclosure requirements for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to strict listing standards including minimum share prices, market capitalization, and regular financial reporting, companies on the OTC Other tier have significantly fewer, or often no, public disclosure requirements. This tier is typically associated with companies that are very early-stage, distressed, or have limited public interest, leading to higher investment risk.
- OTC Tier: OTC Other
- Extremely limited or unknown public financial disclosure, making fundamental analysis nearly impossible.
- Very low liquidity and wide bid-ask spreads, leading to difficulty in buying or selling shares.
- Lack of regulatory oversight compared to major exchanges, increasing potential for fraud or mismanagement.
- High volatility and susceptibility to speculative trading due to limited information and small market cap.
- Potential for delisting or further deterioration of trading status if disclosure remains unknown or inadequate.
- Verify any available financial statements, even if unaudited, for recent operational performance.
- Research any news or press releases from the company or third-party sources for business updates.
- Investigate the company's management team beyond the CEO's name for experience and track record.
- Assess the current status and progress of its drug development pipeline, if any information is available.
- Understand the company's capital structure, including outstanding shares and potential dilution.
- Evaluate the legal and regulatory environment for OTC Other companies and associated risks.
- Consult with a financial advisor experienced in micro-cap and OTC investments.
- Incorporation in 1998 and name change in 2008 suggests a long-standing corporate entity, not a recent shell company.
- Headquarters in Vernon Hills, Illinois, provides a physical location for operations.
- Clear articulation of business focus on discovering, developing, and commercializing therapeutics for specific pain management indications.
- Management of 9 employees indicates an active, albeit small, operational team.
- Focus on specific, complex therapeutic areas (e.g., episodic cluster headache) suggests a specialized scientific endeavor.
Common Questions About WPHM (Healthcare)
What are the main risks for WPHM?
Winston Pharmaceuticals, Inc. faces several significant risks inherent to its stage and industry. Financially, the company exhibits a negative profit margin of -190.4% and negative free cash flow, indicating substantial ongoing losses and a reliance on external funding to sustain operations.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based solely on the provided source data, which is limited, particularly regarding financial specifics beyond margins and FCF, and details on drug pipeline, clinical trials, or commercialization efforts.
- Word count requirements were challenging to meet for some sections (e.g., growth opportunities, company description, investment thesis) without introducing external, non-sourced information. Elaboration focused on implications and general industry context derived from the provided facts.
- The extreme negative Beta value (-982.38) is noted as an outlier, likely indicating very low trading volume or data anomaly rather than a true market correlation.
- CEO profile details are limited due to lack of source data for background and track record.